Modified docetaxel and cisplatin in combination with capecitabine (DCX) as first-tine treatment in HER2-negative advanced gastric cancer

Basit Öğe Kaydı
dc.contributor.authorBilici, Ahmet
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorDemir, Nazan
dc.contributor.authorÖven Ustaalioğlu, Bala Başak
dc.contributor.authorDikillitaş, Mustafa
dc.contributor.authorYıldız, Özcan
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:57:42Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:57:42Z
dc.date.issued2014
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description50th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 30-JUN 03, 2014 -- Chicago, IL
dc.descriptionWOS: 000358613200461
dc.description.abstract[Abstract Not Available]
dc.description.sponsorshipAmerican Society of Clinical Oncologyen_US
dc.identifier.citationBilici, A., Selçukbiricik, F., Demir, N., Öven Ustaalioğlu, B. B., Dikillitaş, M. ve Yıldız, Ö. (2014). Modified docetaxel and cisplatin in combination with capecitabine (DCX) as first-tine treatment in HER2-negative advanced gastric cancer. 50th Annual Meeting of the American-Society-of-Clinical-Oncology, Chicago, IL: American Society of Clinical Oncology.
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3033
dc.identifier.volume32
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherAmerican Society of Clinical Oncology
dc.relation.ispartof50th Annual Meeting of the American-Society-of-Clinical-Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectModified Docetaxel
dc.subjectCisplatin
dc.subjectCapecitabine (DCX)
dc.subjectHER2-Negative
dc.subjectGastric Cancer
dc.titleModified docetaxel and cisplatin in combination with capecitabine (DCX) as first-tine treatment in HER2-negative advanced gastric cancer
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Bildiri Koleksiyonu